Burning mouth syndrome: Difference between revisions
From IDWiki
(Created page with "* Syndrome of chronic oral pain * Mostly affects perimenopausal or postmenopaulsa women * Pathophysiology thought to be neuropathic * Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia * Treatments include alpha-lipoic acid (ALA) supplementation, topical clonazepam, gabapentin, combination ALA and gabapentin, Catauma, or bupivacaine") |
mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
* Pathophysiology thought to be neuropathic |
* Pathophysiology thought to be neuropathic |
||
* Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia |
* Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia |
||
* Treatments include [[alpha-lipoic acid]] (ALA) supplementation, topical [[clonazepam]], [[gabapentin]], combination [[ALA]] and [[gabapentin]], [[Catauma]], or [[bupivacaine]] |
* Treatments include [[alpha-lipoic acid]] (ALA) supplementation, topical [[clonazepam]], [[gabapentin]], combination [[ALA]] and [[gabapentin]], [[Catauma]], or [[bupivacaine]][[CiteRef::liu2017bu]] |
||
Latest revision as of 17:22, 19 September 2024
- Syndrome of chronic oral pain
- Mostly affects perimenopausal or postmenopaulsa women
- Pathophysiology thought to be neuropathic
- Pain is characterized as burning of oral mucosa, and may have associated dysgeusia, paresthesia, dysesthesia, and xerostomia
- Treatments include alpha-lipoic acid (ALA) supplementation, topical clonazepam, gabapentin, combination ALA and gabapentin, Catauma, or bupivacaine1
References
- ^ YF Liu, Y Kim, T Yoo, P Han, JC Inman. Burning mouth syndrome: a systematic review of treatments. Oral Diseases. 2017;24(3):325-334. doi:10.1111/odi.12660.
